ASML Stock Drops 6% as Weak Bookings Shadow Earnings Beat
Can ASML's dominant position in AI chipmaking offset a worrying slowdown in traditional semiconductor demand?
Moderna Forecast -8.2%: Plunge as $39 Target Alarms Bulls
Can Moderna’s pipeline story outweigh a brutal valuation reset, or is the latest sell-off warning investors not to chase the rally?
Moderna Flu Vaccine -3.4% After FDA Panel Backs Shot
Can the Moderna Flu Vaccine turn an FDA panel win into a real growth story before Wall Street loses patience?
Moderna Strategy +13%: In Vivo CAR-T Surge Lifts MRNA
Can Moderna Strategy turn a vaccine story into a multi-platform biotech growth engine before the market prices it in?
Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote
Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again?
Moderna Restructuring +6.3% as FDA Momentum Builds
Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test?
Moderna Hantavirus +12% Rally: Can The Surge Last?
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story?
Moderna Patent Settlement +11.3% Surge: Is the $2.25B Hit Worth the Clarity?
Does Moderna’s billion‑dollar patent peace deal finally clear the runway for its mRNA pipeline—or just cap the upside? Moderna Patent Settlement: Why Wall Street Is Cheering the MoveModerna…